Pfizer company headlines, earnings, strategy, leadership, and market-moving business updates.
Market data may be delayed. For informational purposes only. Not investment advice.
Pfizer (PFE) closed at $23.72, down 2.47% from the prior day, according to a market recap published by Yahoo Finance on July 6.
THE APEX TIMES
THE APEX TIMES
A fresh market commentary argues that Pfizer’s stock (PFE) looks inexpensive on broad valuation measures even as recent results and oncology momentum have been mixed.
THE APEX TIMES
Pfizer’s stock closed lower on the day, but the move came in a session where other market indicators were trending better, underscoring how investors are still calibrating sentiment toward the healthcare sector.
THE APEX TIMES
A recent market commentary argues Pfizer could be mispriced by the market’s focus on first-wave GLP-1 leaders, suggesting “better later than never” if the company finds the right path into the fast-growing weight-loss and metabolic-drug category.
THE APEX TIMES
A Yahoo Finance roundup of a r/ValueInvesting bull thesis argues for Pfizer, but the public post offers limited, non-primary detail on the company’s near-term fundamentals.
THE APEX TIMES
Alexandre de Germay, Pfizer’s Chief International Commercial Officer, said in comments reported June 23 by Reuters that China has moved ahead of Europe in how quickly it advances drug innovation and development.
THE APEX TIMES
A reported CFO departure and a clinical development miss have rekindled concerns about Pfizer’s near-term execution and the durability of its product pipeline, with one widely discussed valuation reference tied to roughly $43 billion.
THE APEX TIMES
A U.S. court dismissed Pfizer as a defendant in a federal case alleging generic drug price fixing, finding insufficient evidence tied to Pfizer’s alleged role.
THE APEX TIMES
A new Yahoo Finance opinion piece says Pfizer’s investor appeal may be underappreciated, pointing income-focused buyers toward its dividend even as the shares face a tough sentiment backdrop.
